PUT - SPRINTER OPEN END - NOVO-NORDISK B | Market Closed - Bid/Ask 13:44:26 2024-07-02 EDT | After market 14:57:30 | |||
| 0.94 EUR | +36.23% |
|
1.005 | +6.91% |
| Current month | +13.25% | ||
| 1 month | -50.26% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-02 | 0.94 | +36.23% |
| 24-07-01 | 0.69 | -16.87% |
| 24-06-28 | 0.83 | +6.41% |
| 24-06-27 | 0.78 | -4.88% |
| 24-06-26 | 0.82 | +43.86% |
Real-time Boerse Frankfurt Warrants
Last update July 02, 2024 at 01:44 pm
More quotesStatic data
| Product type | Knock-Out sin Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VD1JKS |
| ISIN | DE000VD1JKS9 |
| Date issued | 2024-03-05 |
| Strike | 1,061 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.69 € |
| Emission volume | N/A |
| Settlement | Por diferencias |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.99 € |
|---|---|
| Lowest since issue | 0.52 € |
| Spread | 0.07 € |
| Spread % | 6.93% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,005
DKK
Average target price
952.2
DKK
Spread / Average Target
-5.22%
- Stock Market
- Certificates
- Certificat
